IGF2BP2 and triple-negative breast carcinoma: To evaluate the translational potential of IGF2BP2 as a cancer treatment target, we examined the expression of IGF2BP2 in patient samples available in TCGA and found that it is significantly overexpressed in multiple cancers, including triple-negative breast cancer (TNBC) (Figures 4G and 4H).